MARKET INTELLIGENCE·CDMO Deal
Samsung Bioepis and Organon Expand Canadian Biosimilar Portfolio with Pyzchiva (Ustekinumab Biosimilar) Deal
Samsung Bioepis and Organon have expanded their Canadian biosimilar collaboration to include Pyzchiva, a ustekinumab biosimilar, targeting a 2026 launch. Organon secures exclusive commercialization rights in Canada, while Samsung Bioepis handles development and manufacturing. This strategic move expands their joint portfolio to six products, intensifying competition and offering new procurement avenues for healthcare systems and pharmaceutical buyers.
90-Day Activity